Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
BUSINESS
Regeneron Bolsters Japan Oncology Team as Libtayo Gains Ground
Regeneron is deepening its foothold in Japan’s oncology market, adding over 50 sales reps this summer as it looks to capitalize on the expanded use of Libtayo (cemiplimab) and build on the country’s role as a priority market for future…
To read the full story
Related Article
- Regeneron to Upsize Japan Workforce after Libtayo Transfer
February 13, 2025
- Regeneron to Hire 73 Rhinology Sales Reps to Back Dupixent Label Expansion
August 28, 2024
- Regeneron Takes Over Japan Marketing Authorization for Libtayo from Sanofi
June 4, 2024
- Regeneron Set for Commercial Expansion in Japan, Eyes Dupixent Ramp-Up
May 1, 2024
- Regeneron to Make Japan Debut with Dupixent Copromotion
September 27, 2023
BUSINESS
- Eylea Bio-AG to Carry DME Indication Missing from Fuji’s Biosimilar Label
December 5, 2025
- Forxiga Generics Launch in Japan at 33.6% of Originator Price: Sawai, T’s Pharma
December 5, 2025
- Vimpat Copies Hit Shelves at 35% of Originator Price as 10 Firms Flock to Market
December 5, 2025
- Keytruda Extends Japan Sales Lead to 26 Straight Months in November: Encise
December 5, 2025
- Meiji Pharma Takes Stake in Lyric Bio to Back Next-Gen IVIg Manufacturing
December 5, 2025
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…